Is Lenapavir Sodium/Salanka a preventive or therapeutic drug?

Lenapavir sodium/Lenacapavir is a long-acting HIV-1 capsid inhibitor that is currently mainly positioned as a therapeutic drug rather than a preventive drug. Its core mechanism of action is to block multiple links of the virus replication cycle, including virus entry into cells, nucleic acid reverse transcription, and virus assembly processes, by binding to the capsid protein of the HIV virus. This multi-step blocking feature gives lenapavir sodium a unique position in antiretroviral therapy (ART) regimens, especially for patients with drug resistance or treatment failure.

In clinical practice, lenapavir sodium is often used in combination with other antiretroviral drugs to enhance the virological suppression effect. For those patients who have received multiple treatments but still have drug-resistant mutations, lenapavir sodium provides a new option that delays viral progression and improves quality of life. Its long-acting injection form can be injected every 6 months. This low-frequency administration method greatly improves the patient's treatment compliance and reduces the risk of missed doses.

There is currently no authoritative guideline to clearly include napavir sodium in the routine use of HIV pre-exposure prophylaxis (PrEP) Although its pharmacokinetics and long-acting characteristics show certain preventive potential, its main application population at this stage is still confirmed HIV infection (AIDS) patients. Unlike tenofovir, emtricitabine and other drugs that have been used in PrEP, lenapavir sodium focuses more on solving the problems of drug resistance and compliance. As research deepens in the future, if its effectiveness and safety in preventing HIV infection can be proven, it is not ruled out that the indications may be expanded into the prevention field, but currently it is still positioned as a treatment.

Therefore, lenapavir sodium is an innovative therapeutic long-acting antiretroviral drug, rather than a preventive drug in the traditional sense. Patients need to be evaluated by a doctor before use, and combined with genetic resistance testing and disease characteristics to determine whether it is suitable for use to ensure maximum efficacy and safety.

Reference materials:https://www.drugs.com/sunlenca.html